Deep brain stimulation for treatment-resistant depression

American Journal of Psychiatry

Volumn 167, Issue 12, 2010, Pages 1437-1444

  Holtzheimer III, Paul E ^a   Mayberg, Helen S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CLONAZEPAM; DEXAMPHETAMINE; DULOXETINE; LITHIUM; MIRTAZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADD ON THERAPY; ADULT; BEDTIME DOSAGE; BRAIN DEPTH STIMULATION; CASE REPORT; CLINICAL FEATURE; COGNITIVE THERAPY; CONFERENCE PAPER; DRUG DOSE TITRATION; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MALE; NEUROIMAGING; PHOTOTHERAPY; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

ADULT; DEEP BRAIN STIMULATION; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; MALE;

EID: 78649741986     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.10010141     Document Type: Conference Paper

References (70)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617-627 (Pubitemid 40973437)
2. Nierenberg AA, Amsterdam JD: Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51(suppl):39-47
3. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-1917
4. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB: The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59:608-619
5. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM: The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002; 63:963-971 (Pubitemid 35388053)
6. Fawcett J, Harris SG: Suicide in treatment-refractory depression, in Treatment-Resistant Mood Disorders. Edited by Amsterdam JD, Hornig M, Nierenberg AA. New York, Cambridge University Press, 2001, pp 479-488
7. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH: Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987; 44:473-480
8. Thase M, Rush A: When at first you don't succeed: sequential strategies for antidepressant non-responders. J Clin Psychiatry 1997; 58(suppl 13):23-29 (Pubitemid 28011969)
9. Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53:649-659
10. Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ: A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009; 70:177-184
11. Berlim MT, Turecki G: What is the meaning of treatment resistant/refractory major depression (TRD)? a systematic review of current randomized trials. Eur Neuropsychopharmacol 2007; 17:696-707
12. Berlim MT, Turecki G: Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52:46-54
13. Holtzheimer PE 3rd, Nemeroff CB: Emerging treatments for depression. Expert Opin Pharmacother 2006; 7:2323-2339
14. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739-752
15. Fava GA, Savron G, Grandi S, Rafanelli C: Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997; 58:278-282 (Pubitemid 27318573)
16. Kocsis JH, Gelenberg AJ, Rothbaum BO, Klein DN, Trivedi MH, Manber R, Keller MB, Leon AC, Wisniewski SR, Arnow BA, Markowitz JC, Thase ME: Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry 2009; 66:1178-1188
17. Fava GA, Ruini C, Rafanelli C, Finos L, Conti S, Grandi S: Sixyear outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004; 161:1872-1876 (Pubitemid 39314682)
18. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005; 62:417-422
19. Bockting CL, Spinhoven P, Wouters LF, Koeter MW, Schene AH: Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study. J Clin Psychiatry 2009; 70:1621-1628
20. Stimpson N, Agrawal N, Lewis G: Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: systematic review. Br J Psychiatry 2002; 181:284-294 (Pubitemid 35178559)
21. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA: Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996; 153:985-992
22. Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, Mueller M, Bernstein HJ, O'Connor K, Smith G, Biggs M, Bailine SH, Malur C, Yim E, McClintock S, Sampson S, Fink M: Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006; 63:1337-1344
23. Sackeim HA, Dillingham EM, Prudic J, Cooper T, McCall WV, Rosenquist P, Isenberg K, Garcia K, Mulsant BH, Haskett RF: Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry 2009; 66:729-737
24. Rose D, Fleischmann P, Wykes T, Leese M, Bindman J: Patients' perspectives on electroconvulsive therapy: systematic review. BMJ 2003; 326:1363
25. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J: Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285:1299-1307
26. Holtzheimer PE 3rd, Russo J, Avery DH: A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull 2001; 35:149-169
27. Burt T, Lisanby SH, Sackeim HA: Neuropsychiatric applications of transcranial magnetic stimulation: a meta-analysis. Int J Neuropsychopharmacol 2002; 5:73-103 (Pubitemid 34241070)
28. Kozel FA, George MS: Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract 2002; 8:270-275
29. O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62:1208-1216
30. Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, Gilmer W, Marangell LB, Aaronson S, Daskalakis ZJ, Canterbury R, Richelson E, Sackeim HA, George MS: Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009; 34:522-534
31. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58:347-354
32. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P: A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005; 58:364-373
33. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005; 58:355-363
34. Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, Martinez JM, George MS: Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005; 66:1097-1104 (Pubitemid 41442274)
35. Sackeim HA, Brannan SK, Rush AJ, George MS, Marangell LB, Allen J: Durability of antidepressant response to vagus nerve stimulation (VNSTM). Int J Neuropsychopharmacol 2007; 10:817-826
36. Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser I, Bajbouj M, O'Keane V, Corcoran C, Adolfsson R, Trimble M, Rau H, Hoff HJ, Padberg F, Muller-Siecheneder F, Audenaert K, Van den Abbeele D, Stanga Z, Hasdemir M: Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med 2008; 38:651-661
37. Drevets WC, Price JL, Furey ML: Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008; 213:93-118
38. Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004; 161:1957-1966 (Pubitemid 39441394)
39. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW: Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93:3908-3913
40. Sheline YI, Gado MH, Price JL: Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9:2023-2028
41. Hastings RS, Parsey RV, Oquendo MA, Arango V, Mann JJ: Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology 2004; 29:952-959
42. MacQueen GM: Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34:343-349
43. Frodl T, Jager M, Smajstrlova I, Born C, Bottlender R, Palladino T, Reiser M, Moller HJ, Meisenzahl EM: Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci 2008; 33:423-430
44. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM: Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression: controlled magnetic resonance imaging study. Br J Psychiatry 1998; 172:527-532
45. Sheline YI, Gado MH, Kraemer HC: Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160:1516-1518
46. Zhang TJ, Wu QZ, Huang XQ, Sun XL, Zou K, Lui S, Liu F, Hu JM, Kuang WH, Li DM, Li F, Chen HF, Chan RC, Mechelli A, Gong QY: Magnetization transfer imaging reveals the brain deficit in patients with treatment-refractory depression. J Affect Disord 2009; 117:157-161
47. Taylor WD, Kuchibhatla M, Payne ME, Macfall JR, Sheline YI, Krishnan KR, Doraiswamy PM: Frontal white matter anisotropy and antidepressant remission in late-life depression. PLoS One 2008; 3:e3267
48. Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP: Chronic, treatment-resistant depression and right fronto-striatal atrophy. Br J Psychiatry 2002; 180:434-440
49. Hornig M, Mozley PD, Amsterdam JD: HMPAO SPECT brain imaging in treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21:1097-1114
50. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ: Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 2009; 65:792-800
51. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, Fox PT: Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997; 8:1057-1061
52. Dougherty DD, Weiss AP, Cosgrove GR, Alpert NM, Cassem EH, Nierenberg AA, Price BH, Mayberg HS, Fischman AJ, Rauch SL: Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression. J Neurosurg 2003; 99:1010-1017
53. Drevets WC, Bogers W, Raichle ME: Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002; 12:527-544
54. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34-41
55. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr: Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001; 58:631-640
56. Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS: Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007; 164:778-788
57. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45:651-660
58. Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR, Benkelfat C, Ghika J: Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002; 59:1427-1429
59. Stefurak T, Mikulis D, Mayberg H, Lang AE, Hevenor S, Pahapill P, Saint-Cyr J, Lozano A: Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord 2003; 18:1508-1516
60. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont D, Cornu P, Pidoux B, Samson Y, Agid Y: Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340:1476-1480
61. Mayberg HS: Targeted electrode-based modulation of neural circuits for depression. J Clin Invest 2009; 119:717-725
62. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64:461-467
63. Jimenez F, Velasco F, Salin-Pascual R, Hernandez JA, Velasco M, Criales JL, Nicolini H: A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery 2005; 57:585-593
64. Greenberg BD, Nahas Z, Carpenter LL: Current status of deep brain stimulation. Primary Psychiatry 2005; 12:59-64
65. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE: Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010; 67:110-116
66. Sartorius A, Kiening KL, Kirsch P, von Gall CC, Haberkorn U, Unterberg AW, Henn FA, Meyer-Lindenberg A: Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry 2010; 67:e9-e11
67. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA: Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31:2384-2393
68. Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD: Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009; 65:267-275
69. Schatzberg AF, Kraemer HC: Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry 2000; 47:736-744
70. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Leurgans S: Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008; 23:690-699